107 related articles for article (PubMed ID: 22112973)
1. The validation of matrix metalloproteinase-9 mRNA gene expression as a predictor of outcome in patients with metastatic gastric cancer.
Al-Batran SE; Pauligk C; Wirtz R; Werner D; Steinmetz K; Homann N; Schmalenberg H; Hofheinz RD; Hartmann JT; Atmaca A; Altmannsberger HM; Jäger E
Ann Oncol; 2012 Jul; 23(7):1699-705. PubMed ID: 22112973
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer.
Kwon HC; Roh MS; Oh SY; Kim SH; Kim MC; Kim JS; Kim HJ
Ann Oncol; 2007 Mar; 18(3):504-9. PubMed ID: 17322540
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of MMP-11 correlate with clinical outcome in Chinese patients with advanced gastric adenocarcinoma.
Yan D; Dai H; Liu JW
BMC Cancer; 2011 Apr; 11():151. PubMed ID: 21513571
[TBL] [Abstract][Full Text] [Related]
4. Expression of matrix metalloproteinase-9 mRNA and vascular endothelial growth factor protein in gastric carcinoma and its relationship to its pathological features and prognosis.
Yang Q; Ye ZY; Zhang JX; Tao HQ; Li SG; Zhao ZS
Anat Rec (Hoboken); 2010 Dec; 293(12):2012-9. PubMed ID: 21089052
[TBL] [Abstract][Full Text] [Related]
5. Differential effect of MMSET mRNA levels on survival to first-line FOLFOX and second-line docetaxel in gastric cancer.
Wei J; Costa C; Shen J; Yu L; Sanchez JJ; Qian X; Sun X; Zou Z; Gimenez-Capitan A; Yue G; Guan W; Rosell R; Liu B
Br J Cancer; 2014 May; 110(11):2662-8. PubMed ID: 24809779
[TBL] [Abstract][Full Text] [Related]
6. Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome.
Glatz T; Bronsert P; Schäfer M; Kulemann B; Marjanovic G; Sick O; Hopt UT; Zirlik K; Makowiec F; Hoeppner J
Eur J Surg Oncol; 2015 Oct; 41(10):1300-7. PubMed ID: 26253194
[TBL] [Abstract][Full Text] [Related]
7. Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.
Shah MA; Janjigian YY; Stoller R; Shibata S; Kemeny M; Krishnamurthi S; Su YB; Ocean A; Capanu M; Mehrotra B; Ritch P; Henderson C; Kelsen DP
J Clin Oncol; 2015 Nov; 33(33):3874-9. PubMed ID: 26438119
[TBL] [Abstract][Full Text] [Related]
8. Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study).
Zaanan A; Samalin E; Aparicio T; Bouche O; Laurent-Puig P; Manfredi S; Michel P; Monterymard C; Moreau M; Rougier P; Tougeron D; Taieb J; Louvet C
Dig Liver Dis; 2018 Apr; 50(4):408-410. PubMed ID: 29409778
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of docetaxel, oxaliplatin, and S-1 therapy in patients with metastatic gastric cancer.
Kim HS; Ryu MH; Zang DY; Ryoo BY; Yang DH; Cho JW; Lim MS; Kim MJ; Han B; Choi DR; Kim JH; Jung JY; Song H; Park CK; Kang YK
Gastric Cancer; 2016 Apr; 19(2):579-585. PubMed ID: 25997815
[TBL] [Abstract][Full Text] [Related]
10. The relationship of vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer.
Oh SY; Kwon HC; Kim SH; Lee S; Lee JH; Hwang JA; Hong SH; Graves CA; Camphausen K; Kim HJ; Lee YS
BMC Cancer; 2013 Feb; 13():43. PubMed ID: 23374220
[TBL] [Abstract][Full Text] [Related]
11. Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan.
Kondoh C; Kadowaki S; Komori A; Narita Y; Taniguchi H; Ura T; Ando M; Muro K
Gastric Cancer; 2018 Nov; 21(6):1050-1057. PubMed ID: 29658055
[TBL] [Abstract][Full Text] [Related]
12. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Al-Batran SE; Hartmann JT; Probst S; Schmalenberg H; Hollerbach S; Hofheinz R; Rethwisch V; Seipelt G; Homann N; Wilhelm G; Schuch G; Stoehlmacher J; Derigs HG; Hegewisch-Becker S; Grossmann J; Pauligk C; Atmaca A; Bokemeyer C; Knuth A; Jäger E;
J Clin Oncol; 2008 Mar; 26(9):1435-42. PubMed ID: 18349393
[TBL] [Abstract][Full Text] [Related]
13. Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer.
Bilici A; Selcukbiricik F; Demir N; Oven Ustaalioglu BB; Dikilitas M; Yildiz O
Asian Pac J Cancer Prev; 2014; 15(20):8661-6. PubMed ID: 25374186
[TBL] [Abstract][Full Text] [Related]
14. Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China.
Zhu Y; Sun Y; Hu S; Jiang Y; Yue J; Xue X; Yang L; Xue L
BMC Gastroenterol; 2017 Mar; 17(1):41. PubMed ID: 28292272
[TBL] [Abstract][Full Text] [Related]
15. Integrin αvβ6 and matrix metalloproteinase 9 correlate with survival in gastric cancer.
Lian PL; Liu Z; Yang GY; Zhao R; Zhang ZY; Chen YG; Zhuang ZN; Xu KS
World J Gastroenterol; 2016 Apr; 22(14):3852-9. PubMed ID: 27076771
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel, oxaliplatin, 5-fluorouracil and leucovorin combination chemotherapy in patients with recurrent or metastatic gastric cancer.
Lan YQ; Wu RP; Huang XB; Wang XL; Zhong DT; Huang CY; Song JT
Tumori; 2018; 104(1):22-29. PubMed ID: 28777427
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of intraperitoneal and intravenous chemotherapy for advanced gastric cancer with peritoneal metastasis.
Chen Y; Wang XJ; Lin RB; Chen L; Lin G; Guo ZQ
Tumori; 2014; 100(5):e180-8. PubMed ID: 25343556
[TBL] [Abstract][Full Text] [Related]
18. DNA polymerase η protein expression predicts treatment response and survival of metastatic gastric adenocarcinoma patients treated with oxaliplatin-based chemotherapy.
Teng KY; Qiu MZ; Li ZH; Luo HY; Zeng ZL; Luo RZ; Zhang HZ; Wang ZQ; Li YH; Xu RH
J Transl Med; 2010 Nov; 8():126. PubMed ID: 21110884
[TBL] [Abstract][Full Text] [Related]
19. Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial.
Ochenduszko S; Puskulluoglu M; Konopka K; Fijorek K; Urbanczyk K; Budzynski A; Matlok M; Lazar A; Sinczak-Kuta A; Pedziwiatr M; Krzemieniecki K
Med Oncol; 2015 Oct; 32(10):242. PubMed ID: 26354521
[TBL] [Abstract][Full Text] [Related]
20. Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 study.
Richards D; Kocs DM; Spira AI; David McCollum A; Diab S; Hecker LI; Cohn A; Zhan F; Asmar L
Eur J Cancer; 2013 Sep; 49(13):2823-31. PubMed ID: 23747051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
